首页> 外文期刊>Seminars in cancer biology >Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers
【24h】

Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers

机译:透明细胞肾细胞癌(CCRCC)蛋白质组学表征中的挑战和机遇:朝向肾癌的个性化护理的关键步骤

获取原文
获取原文并翻译 | 示例
       

摘要

Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, comprising approximately 75% of all kidney tumors. Recent the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) studies have significantly advanced the molecular characterization of RCC and facilitated the development of targeted therapies. Such advances have improved the median survival of patients with advanced disease from less than 10 months prior to 2004 to 30 months by 2011. However, approximately 30% of localized ccRCC patients will nevertheless develop recurrence or metastasis after surgical resection of their tumor. Therefore, it is critical to further analyze potential tumor-associated proteins and their profiles during disease progression. Over the past decade, tremendous effort has been focused on the study of molecular pathways, including genomics, transcriptomics, and proteomics in order to identify potential molecular biomarkers, as well as to facilitate early detection, monitor tumor progression and uncover potentially therapeutic targets. In this review, we focus on recent advances in the proteomic analysis of ccRCC, current strategies and challenges, and perspectives in the field. This insight will highlight the discovery of tumor-associated proteins, and their potential clinical impact on personalized precision-based care in ccRCC.
机译:透明细胞肾细胞癌(CCRCC)是最常见的肾癌类型,包含约75%的肾肿瘤。近期癌症基因组阿特拉斯(TCGA)和国际癌症基因组联盟(ICGC)研究具有显着提高了RCC的分子表征,促进了靶向疗法的发展。此类进展在2011年至30月至30个月至30个月之前从不到10个月内提高了晚期疾病的患者的中位数。然而,大约30%的本地化CCRCC患者将在手术切除肿瘤后发生复发或转移。因此,在疾病进展期间进一步分析潜在的肿瘤相关蛋白及其曲线至关重要。在过去的十年中,巨大的努力专注于分子途径的研究,包括基因组学,转录组织和蛋白质组学,以鉴定潜在的分子生物标志物,以及促进早期检测,监测肿瘤进展和揭示潜在的治疗目标。在本综述中,我们专注于CCRCC,当前策略和挑战蛋白质组学分析的最新进展,以及该领域的观点。这种洞察力将突出肿瘤相关蛋白的发现,以及它们对CCRCC中个性化精密护理的潜在临床影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号